Devices and Diagnostics

The Gems You’ll Find at OIS@AAO 2018

The Gems You’ll Find at OIS@AAO 2018

Diamonds are emerging as the new 10th anniversary gift. Here’s a look at a few of gems you can mine at the 10th OIS@AAO in two Thursdays, on October 25, at the Marriott Marquis in Chicago a day before the American Academy of Ophthalmology (AAO) annual meeting gets underway. Breakfast Breakout Sessions. This year’s seven…

Read More

Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

At OIS@ASRS 2016, Forrest Fleming, then CEO of TrueVision Systems, announced a new partnership with Alcon. He also introduced the result of that pairing: the Ngenuity 3D Visualization System for digitally assisted vitreoretinal surgery, featuring TrueVision’s heads-up, three-dimensional imaging technology delivered on Alcon’s platform. Fleming said it would be a platform that would “grow, and…

Read More

MIGS Minus One: What’s Next?

MIGS Minus One: What’s Next?

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class in the micro-invasive glaucoma surgery (MIGS) space will fare. Alcon is, after all, a major player and when it advises surgeons to “immediately cease further implantation” and return unused devices,…

Read More

A Future Vision of Medicine from the Masters of Retina

A Future Vision of Medicine from the Masters of Retina

Two forces are emerging in healthcare that could determine how quickly personalized medicine takes over: an outcomes-based system that pays drug makers only when their treatments work; and more precise diagnostic technology that utilizes artificial intelligence and telemedicine to ensure a high probability that those treatments work. That was the future vision participants on the…

Read More

Seven Steps for Walking the Reimbursement Maze

Seven Steps for Walking the Reimbursement Maze

WASHINGTON, DC – Getting insurers to reimburse for novel ophthalmic devices and procedures has been getting harder, but by planning early, involving the right employees, and having a defined path to reimbursement, companies can still achieve success. This was the advice given by panelists at OIS@ASCRS 2018. Here are seven takeaways from the session on…

Read More

Keeping the MIGS Explosion in Perspective

Keeping the MIGS Explosion in Perspective

WASHINGTON, DC – When Stanford University ophthalmology professor Kuldev Singh, MD, MPH, underwent medical training 25 years ago, there were maybe five to six non-pharmaceutical treatment options to manage glaucoma. Today, there are some 17 different approaches, he said during a session on microincisional glaucoma surgery (MIGS) at the OIS@ASCRS meeting, and more are on…

Read More

15 Things We Learned at OIS@ASCRS

Takeaways from OIS@ASCRS 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision accommodating intraocular lens implanted. The average objective accommodation at six months measured 2.00 diopters, he said. For the first time, Keranova presented preclinical results of its all-in-one cataract surgery platform.…

Read More

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on public market activity and “Masters of the Industry,” and a new panel on frontiers in femtosecond lasers. It’s all set for next Thursday, April…

Read More

Will ODs Take Over Ocular Surface Disease Treatment?

Can ODs Take Over Ocular Surface Disease?

Over the past decade, the treatment of ocular surface conditions such as dry eye and meibomian gland dysfunction (MGD) has evolved from “pats on the back” and warm compresses to innovative and effective tools and drugs, including Shire’s Xiidra, Allergan’s TrueTear (and, of course, Restasis), and Johnson & Johnson Vision Care’s (J&J VC) LipiFlow and…

Read More

A Look Behind ReVision Optics’ Shuttered Door

Why ReVision Optics Shut Down

By Larry Haimovitch and Richard Mark Kirkner Someday for some company, the business of selling corneal inlays to treat presbyopia could be very lucrative, but that day is not today and that company is not ReVision Optics, which abruptly closed its doors last week. ReVision Optics developed the Raindrop Near Vision Inlay to correct presbyopia.…

Read More